EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study

Yuen Tsang, Michael Stokes iD, Yong-Jin Kim, Rong Tilney, Sumeet Panjabi

The Clinical Respiratory Journal · 2023

DOI: 10.1111/crj.13704 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Clinical Respiratory Journal, 2023. Verfasst von Yuen Tsang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Real-World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Actelion, Actelion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral selexipag, a prostacyclin pathway agent (PPA), is effective in patients with pulmonary arterial hypertension (PAH). The objective of this study is to assess the impact of initiating oral selexipag within 12 months of diagnosis on health outcomes.

Methods

This retrospective cohort study used data from Optum's de‐identified Clinformatics® Data Mart Database. PAH patients between 1 October 2015 and 30 September 2019 were included. Patients were also required to have received PAH medication within 12 months of their initial diagnosis. Study groups included patients who initiated selexipag within 12 months of PAH diagnosis (SEL ≤ 12) and those who did not initiate any PPA within 12 months of PAH diagnosis (No PPA ≤ 12). Inverse probability of treatment weighting was used to remove potential confounding between groups. Cox and Poisson regression models were used to compare hospitalization and disease progression. Generalized linear model with gamma distribution and log link was used to compare costs.

Results

SEL ≤ 12 had lower rate of all‐cause hospitalizations (rate ratio: 0.76, 95% confidence interval [CI]: 0.60, 0.96) versus no PPA ≤ 12, but no differences in PAH‐related hospitalization rate (rate ratio: 1.03, 95% CI: 0.79, 1.33) or risk of disease progression (hazard ratio: 1.01, 95% CI: 0.71, 1.44). SEL ≤ 12 incurred lower all‐cause (mean difference: −$23 623; 95% CI: −35 537, −8512) and PAH‐related total medical costs (mean difference: −$12 927; 95% CI: −19 559, −5679) versus no PPA ≤ 12.

Conclusion

Selexipag initiation within 12 months of PAH diagnosis demonstrated reductions in all‐cause hospitalization rate and medical costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionHypertension, PulmonaryHumansAntihypertensive AgentsRetrospective StudiesFamilial Primary Pulmonary HypertensionHospitalizationDisease ProgressionAcetamidesPyrazines

Stichwörter der Autor:innen

costdisease progressionhospitalizationprostacyclin pathway agentpulmonary arterial hypertensionselexipag

Substanzen

Antihypertensive AgentsselexipagAcetamidesPyrazines

Autor:innen und Institutionen

  • Real-World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Data Analytics, Evidera, St-Laurent, Quebec, Canada.
  • Data Analytics, Evidera, Waltham, Massachusetts, USA.

ORCID-Profile: Michael Stokes

Förderung

  • Actelion
  • Actelion Pharmaceuticals

Zitieren

APA

Tsang, Y., Stokes, M., Kim, Y. J., Tilney, R., & Panjabi, S. (2023). Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13704

Vancouver

Tsang Y, Stokes M, Kim YJ, Tilney R, Panjabi S. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study. The Clinical Respiratory Journal. 2023. doi:10.1111/crj.13704

BibTeX
@article{Tsang2023,
  author = {Tsang, Yuen and Stokes, Michael and Kim, Yong-Jin and Tilney, Rong and Panjabi, Sumeet},
  title = {Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study},
  journal = {The Clinical Respiratory Journal},
  year = {2023},
  doi = {10.1111/crj.13704}
}
Kostenlos starten →